Immunitor Completes Business Trip to China and Presents at Chinese Academy of Science Annual TB Meeting
13 Dezembro 2010 - 1:10PM
Immune Network Ltd. (Pink Sheets:IMMFF), advises that Immunitor has
concluded a successful business trip to China and presented new
clinical data to experts at the Chinese Academy of Sciences TB
conference in Beijing.
Immunitor conducted a series of meetings with Chinese
pharmaceutical companies interested in Immunitor's lead product,
V5. Various deal arrangements were discussed comprising
establishment of joint venture and marketing arrangements for V5,
for both hepatitis B and C, and tuberculosis indications, including
MDR-TB (multi-drug resistant tuberculosis). Given the urgency of
treating such diseases as MDR-TB and the overall size of commercial
opportunity in China for V5 and the marketing efforts that will be
required, Immunitor and its business partner Vancouver-based Immune
Network Ltd. are seeking a well-established company in China which
will contribute to registration and commercialization of this
product. The importance of the market for V5 in China cannot be
overemphasized: about 40% of China's population carries the
tuberculosis bacilli, 690 million are carriers of hepatitis B virus
(HBV), and 40 million are carriers of hepatitis C virus
(HCV).
Immunitor's business trip coincided with the Annual TB meeting
of the Chinese Academy of Sciences held at Beijing Chest Hospital –
the largest tuberculosis hospital in China. Immunitor's talk,
entitled "Immunotherapy of TB," was received with great interest by
leading TB experts of China. The presentation disclosed interim
results from Immunitor's imm01 phase 2b placebo-controlled trial
involving 120 patients that is near completion (see
http://clinicaltrials.gov/ct2/show/NCT01222338 for
details). Trials with V5 have thus far revealed highly
encouraging results for treatment of all forms of tuberculosis,
including difficult-to-treat forms of TB such as relapsed TB,
re-treated or failure TB, drug-resistant MDR-TB, as well as TB-HIV
(and MDR-TB with HIV), all apparently curable at the same efficacy
rate as drug-sensitive TB. These new data on the use of V5 in
tuberculosis patients will provide insight into the endpoints that
will guide Immunitor in the design of follow-on studies, now being
arranged in several countries of Africa and Asia.
China has the world's second largest tuberculosis epidemic,
closely trailing after India. About 25% of all new TB cases,
and half of all previously-treated cases, are resistant to at least
one TB drug. Prevalence of MDR-TB cases is often
underestimated. "I first came to China back in 1986 and since
then have built a solid network of business and academic
connections. This historically strong relationship with China will
help us to accelerate our market strategies in the area of TB and
hepatitis. Beijing Chest Hospital is the leading clinical site for
trials of new TB drugs" said Dr Aldar Bourinbaiar, CEO of
Immunitor. Over 40% of Chinese residents have the latent form of TB
and the number of individuals with chronic hepatitis B in China is
largest in the world, affecting close to 150 million people. For
additional information about Immunitor company, please visit
www.immunitor.com.
Immune Network is continuing its work toward meeting the
pre-conditions for completion of a transaction with
Immunitor. Several corporate updates and proposal of terms for
Immune Network's transaction with Immunitor will be announced this
month. A temporary website for Immune Network is at
http://www.immune-network.com.
The Immune Network Ltd. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=8008 .
Safe Harbor Statement
The information in this release, other than historical
information, may be considered forward-looking statements within
the provisions of the Private Securities Litigation Reform Act of
1995. Projection and other forward-looking statements and
management expectations regarding future events and/or financial
performance of the Company -- although given in good faith -- are
inherently uncertain and actual events and/or results may differ
materially.
CONTACT: Immune Network Ltd
IMMFF@yahoo.com
Omni Bridgeway (PK) (USOTC:IMMFF)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Omni Bridgeway (PK) (USOTC:IMMFF)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024